The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
With sales of the Amgen KRAS inhibitor flatlining an advisory panel is called to discuss its continued US approval.
However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.
PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.
Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.
Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.